Role Of Phospholipid Transfer Proteins (Pltp) On Endotoxemia Caused By Buccal Inflammation
NCT ID: NCT01950962
Last Updated: 2019-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
242 participants
INTERVENTIONAL
2010-10-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mechanisms of Acute Inflammation Following Periodontal Treatment
NCT05178563
Periodontitis and Inflammation
NCT04831060
Evaluation of Local Doxycycline in Smokers With Chronic Periodontitis
NCT02726646
Immunoregulation of Periodontal Diseases
NCT02567019
PERIodontal Disease, Microbiota and Miscarriage
NCT06576622
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
slight periodontal disease
Sampling of blood
moderate periodontal disease
Sampling of blood
severe periodontal disease
Sampling of blood
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sampling of blood
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Persons who have provided written informed consent
* Patients with periodontal disease whatever the severity with at least one molar or one premolar on the dental arch
* Possibility to examine the oral cavity (patient able to open mouth)
* Possibility to do an orthopantomogram (sitting position required and patient able to clench jaws)
* Patient able to understand French
* Patient who accepts to provide fasting blood sample within the five days following the initial consultation
\- Patient present for the fasting blood sample within five days following the initial consultation Patients will be matched for sex and, as much as possible, for age in the three groups and for the severity of the periodontal disease
Exclusion Criteria
* Patients with a high risk of infectious endocarditis who require prophylaxis for any medical act involving blood
* Patients who have taken at least once during the 8 days preceding the definitive inclusion an anti-inflammatory dose of NSAIDS and/or a salicylate (blood sample)
* Patients who have had long-term treatment (\>6 months) with corticoids at a dose of at least 15 mg per day
* Patients on antibiotics less than 15 days before the blood sample
* Patients with oral inflammation requiring treatment with antibiotics or anti-inflammatory drugs during the pre-inclusion
* Scaling during the 24 hours before the blood sample
* History of oral cancer or cancer of the pharynx
* Active cancer (patient undergoing treatment or diagnosis within the previous 5 years)
* Iatrogenic, spontaneous or therapeutic immunodepression (patient on immunosuppressants or antiretrovirals),
* Systemic or organ specific inflammatory syndrome not related to the periodontal disease
* proven bacterial, viral or fungal Infection either developing or being treated (urinary, prostate infection)
* Inflammatory cancer (solid tumour, malignant hemopathy)
* Pregnancy
* Impossibility to cooperate due to a psychiatric disease, dementia
* Patients unable to understand the protocol
35 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Dijon
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Lafon PHRC IR 2010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.